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Abstract
Background/Aims: CRISPR-Cas9, a RNA-guided targeted genome editing tool, has 
revolutionized genetic engineering by offering the ability to precisely modify DNA. GPRC5B is 
an orphan receptor belonging to the group C family of G protein-coupled receptors (GPCRs). 
In this study, we analysed the functional roles of the Gprc5b receptor in MIN6 β-cells using 
CRISPR-Cas9 and transient over-expression of Gprc5b. Methods: The optimal transfection 
reagent for use in MIN6 β-cells was determined by analysing efficiency of GFP plasmid delivery 
by cell sorting. A MIN6 β-cell line in which Gprc5b expression was knocked down (Gprc5b 
KD) was generated using CRISPR-Cas9 technology. Gprc5b receptor mRNA expression, 
proliferation, apoptosis, Cignal 45-Pathway Reporter Array signalling and western blot assays 
were carried out using Gpcr5b KD MIN6 β-cells that had been transiently transfected with 
different concentrations of mouse Gprc5b plasmid to over-express Gprc5b. Results: JetPRIME® 
was the best candidate for MIN6 β-cell transfection, providing approximately 30% transfection 
efficiency. CRISPR-Cas9 technology targeting Gprc5b led to stable knock-down of this receptor 
in MIN6 β-cells and its re-expression induced proliferation and potentiated cytokine- and 
palmitate-induced apoptosis. The Cignal 45 Reporter analysis indicated Gprc5b-dependent 
regulation of apoptotic and proliferative pathways, and western blotting confirmed activation 
of signalling via TGF-b and IFNg. Conclusion: This study provides evidence of CRISPR-Cas9 
technology being used to down-regulate Gprc5b expression in MIN6 β-cells. This strategy 
allowed us to identify signalling pathways linking GPRC5B receptor expression to b-cell 
proliferation and apoptosis.
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IntroductionThe simplicity of the CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9) system has revolutionized genome engineering. Initially described as an adaptive immune system in bacteria, it has been extensively 
developed as an RNA-guided genome editing tool, allowing precise manipulation of specific genomic loci and facilitating detailed investigation of targeted gene functions or diseases. CRISPR-Cas9 technology has been used for genome editing in induced pluripotent stem cells [1, 2] primary human endothelial cells [3] and the INS-1 [4, 5] and MIN6 [6, 7] β-cell lines, among others.G protein-coupled receptors (GPCRs) constitute the largest family of transmembrane receptors encoded by the human genome [8], being targeted for the treatment of diseases such as diabetes and its associated complications [9]. Orphan GPCRs, whose endogenous 
ligand has not yet been identified, exhibit an appealing source of undiscovered therapeutic potential. GPRC5B, also known as retinoic acid-inducible gene 2 (Raig2), is a member of the Raig subfamily of type 3 (family C) GPCRs [10]. This orphan receptor is highly expressed in human and mouse islets [11], brain [12] and white adipose tissue [13]. Observations that it is up-regulated in islets from donors with type 2 diabetes (T2D) [11] and that its deletion in mice causes glucose intolerance [13] suggest that it may be involved in the pathogenesis of diabetes, but the molecular mechanisms underlying this remain unclear.
As there are no known specific agonists for Gprc5b we have previously used lentivirus to down-regulate Gprc5b in islets and we demonstrated that this confers protection against 
apoptosis [11]. In the current study, we have generated isogenic MIN6 β-cell clones in which 
Gprc5b has been specifically and stably knocked down using the CRISPR-Cas9 technology. We have then reintroduced Gprc5b in a graded fashion to determine the effects on b-cell proliferation and apoptosis, and the cell signalling pathways downstream of Gprc5b in 
b-cells.
Materials and Methods
ReagentsFuGENE® 6 Transfection Reagent, Dual-Glo® Luciferase Assay System kits, anti-mouse and anti-rabbit IgG (H+L), HRP-conjugated secondary antibodies and caspase 3/7 assay kits were from Promega UK (Southampton, UK). The mouse Gprc5b antibody was from Biorbyt (Cambridge, UK). Linear polyethylenimine was from Polysciences, Inc. (Hirschberg an der Bergstrasse, Germany), Metafectene® Pro from Cambio (Cambridge, UK), jetPRIME® from Polyplus-transfection (Illkirch, France), TorpedoDNA transfection reagent 
from Thistle Scientific Ltd. (Glasgow, UK) and Lipofectamine® 2000 Transfection Reagent and Pierce™ BCA 
Protein Assay Kit were from Thermo Fisher Scientific (Loughborough, UK). NanoJuice® Transfection Kit was from Millipore (U.K.) Ltd. (Hertfordshire, UK). Attractene Transfection Reagent, DNeasy Blood & Tissue kits and Cignal 45-Pathway Reporter Array kits were from Qiagen Ltd. (Manchester, UK). Recombinant 
murine TNFα, IFNg and IL-1β were from PeproTech EC Ltd. (London, UK). The BrdU cell proliferation kit 
was from Sigma-Aldrich (Dorset, UK). Gprc5b double nickase plasmid (mouse) and anti-β-actin antibody were from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany). Anti-Smad2/3, anti-STAT1, anti-Smad2/3 (phospho T8) and anti-STAT1 (phospho S727) antibodies were from Abcam plc. (Cambridge, UK). All other 
chemicals were from Sigma Aldrich or Thermo Fisher Scientific.
Cell culture
MIN6 β-cells (passage 25-45), were maintained in culture in a humidified incubator at 37°C, 5% CO2, 
95% air in DMEM supplemented with 25 mM glucose, 2 mM glutamine, 10% FBS, 100 units/ml penicillin, 
100 µg/ml streptomycin and 100 µM 2-mercaptoethanol. The Gpcr5b KD MIN6 β-cell line was cultured with the same medium, which was also supplemented with 1.5 µg/ml puromycin as the resistance selection antibiotic.
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Screening of MIN6 β-cell transfection efficiencyApproximately 200,000 MIN6 b-cells were seeded into 12-well cell culture plates and maintained in culture overnight, then transfected with a plasmid encoding GFP using a range of commercially available transfection reagents (FuGENE® 6, Linear polyethylenimine, Metafectene® Pro, jetPRIME®, TorpedoDNA, 
Lipofectamine® 2000, NanoJuice® and Attractene) following the manufacturers’ instructions. Cells were incubated for 48 hours after transfection, retrieved by trypsinisation then resuspended in 1 ml of sterile 
PBS. GFP production by transfected cells was analysed using a cell sorter that excited GFP fluorescence 
with a blue laser at 488nm (BD FACSAria III, Flow Cytometry Facilities, Guy’s Hospital, London), and the 
expression was plotted versus fluorescence of untransfected MIN6 β-cells (GFP negative).
Gprc5b receptor knockout in MIN6 β-cells using CRISPR-Cas9 technologyBased on previous reports of a link between GPRC5B and T2D, we generated a stable Gpcr5b KD MIN6 
β-cell line using CRISPR-Cas9 technology to investigate the direct role of this receptor in β-cell function. For 
this purpose, approximately 500,000 MIN6 β-cells were seeded into 6-well cell culture plates, maintained in culture overnight and transfected using jetPRIME® with 1 µg of a Gprc5b double nickase plasmid set that consists of a pair of plasmids, each encoding a D10A mutated Cas9 nuclease and a unique, target-
specific 20 nt guide RNA (gRNA). Each pair of gRNA sequences are offset by approximately 20 bp to allow 
for high specificity gene knockout. The specific regions of the Gprc5b gene targeted by these plasmids are GCTCTTCGTGATCACCTCGG and GAAAACGCCAGCACATCCCG. This strategy was employed to induce Gpcr5b-
targeted double strand breaks in MIN6 β-cells at the genomic locus at chromosome 7 (region F2, exon 4). 
Cells were maintained in culture for 48 hours at 37°C post-transfection then transferred into 96 well plates using a cell dilution method to allow isolation of single colonies (genome-targeted monoclonal cell clones). The culture medium was supplemented with 1.5 µg/ml puromycin to allow selection of cells expressing the transfected plasmids. After growing and generating stocks, the isogenic colonies were expanded, genomic 
DNA was extracted from each clone and expression of the CRISPR Gprc5b knockout sequence flanking the 
deleted region was confirmed by PCR using primers (forward: 5’-CTGAGGAAAGGAGCACGT-3’ and reverse: 
5’-CACAGGGCTCTTCTTCTCCTT-3’) and subsequent Sanger sequencing (Source Bioscience).
RNA extraction and quantitative real-time PCR
Groups of approximately 200,000 Gpcr5b KD MIN6 β-cells were seeded into 6-well plates, maintained in culture overnight and transfected with increasing concentrations of mouse Gprc5b plasmid (0.01, 0.1, 1, 
10 and 100%, bulked to 100% DNA with pcDNA3 vector to ensure the same amount of DNA per condition 
tested) using jetPRIME®. Un-transfected WT MIN6 β-cells were used as controls. After 48 hours total RNA 
was extracted using a modified TRIzol protocol [14] and Gprc5b, Nodal and DP5 (Hrk) gene expression relative to the house-keeping gene GAPDH was determined using QuantiTect qPCR assays, as described elsewhere [15, 16]. All gene primer efficiency (E) [17] values were in the range of 1.85–2.15. For all gene 
quantifications, template cDNAs were diluted such that all quantified genes returned Ct values <30.
Proliferation
Groups of 10,000 Gpcr5b KD MIN6 β-cells were seeded into 96-well plates and transfected the 
following day with increasing concentrations of mouse Gprc5b plasmid (0.01, 0.1, 1, 10 and 100%, bulked 
to 100% DNA with pcDNA3) using jetPRIME®. Un-transfected WT MIN6 β-cells were used as controls. After overnight incubation, cells were maintained for a further 24 hours in serum-free medium before being labelled with 100µM BrdU for 4h at 37°C. BrdU incorporation into proliferating b-cells was quantified using a plate reader measuring absorbance at 450 nm [18].
Apoptosis
Groups of 10,000 Gpcr5b KD MIN6 β-cells were seeded into 96-well white opaque cell culture plates and transfected the following day with increasing concentrations of mouse Gprc5b plasmid (0.01, 0.1, 1, 10 
and 100%, bulked to 100% DNA with pcDNA3) using jetPRIME®. Un-transfected WT MIN6 β-cells were 
used as controls. Quantification of basal, cytokine and palmitate-induced b-cell apoptosis was carried out using the Caspase-Glo 3/7 assay kit, essentially as previously described [18].
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Cignal™ Finder 45-Pathway Reporter Array
Pathway reporters were introduced into Gpcr5b KD MIN6 β-cells in 96-well cell culture plates via 
reverse transfection according to the manufacturer’s protocol. Briefly, reporter DNA constructs resident in 
each plate well were resuspended with 50 μl Opti-MEM, together with pcDNA3 (100%) or mouse Gprc5b 
plasmid (10%, bulked with pcDNA3 to 100%) and then mixed with jetPRIME®. Cells were suspended in 
Opti-MEM supplemented with 10% of fetal bovine serum and 0.1 mM non-essential amino acids, and then 
50 μl of the cell suspension, equivalent to 10,000 cells, was added into each plate well and mixed with DNA 
resident in the plate, plasmids and added transfection reagent. The cells were incubated for 48 h at 5% CO2 
and 37 °C. Analysis of 45 signalling pathways in the cells was then carried out using the Cignal 45-Pathway 
Reporter Array kit by quantifying the luminescent signal according to the manufacturer’s instructions. Expression values were normalised by establishing a sample ratio value to discriminate between genuine 
cellular responses (Firefly luminescent signal) and non-specific responses (Renilla luminescent signal), and 
plotted as log2 fold change comparing cells expressing 10% mouse Gprc5b plasmid with those expressing the pcDNA3 control plasmid.
Western BlotGprc5b expression in wildtype MIN6 cells and those transfected with the Gprc5b double nickase plasmid set was determined by western blotting using an anti-Gprc5b antibody at a dilution of 1/100 and 
normalised to beta-actin expression in the same samples (1/2,000 dilution). For identification of signalling downstream of Gprc5b in MIN6 b-cells, groups of approximately 4x106 Gpcr5b KD MIN6 β-cells were seeded 
into T75 flasks, maintained in culture overnight and transfected with 10% mouse Gprc5b plasmid (plus 90% 
of pcDNA3 empty vector) or 100% of pcDNA3 using jetPRIME®. After 48 hours incubation, proteins were 
extracted, fractionated on 4-12% Bis-Tris gels (200V, 1 hour) then immunoprobed on PVDF membranes with antibodies directed against beta-actin (1/2,000), total (1/200) or phosphorylated (1/200) anti-Smad2/3 or total (1/500) or phosphorylated (1/1,000) anti-STAT1 and their respective secondary antibodies.
Statistical analysisGraphPad Prism 5.0 (GraphPad Software, Inc.) was used for statistical analyses. Data are presented 
as mean±SEM and analysed using ANalysis Of VAriance (ANOVA) or Student’s t tests and p<0.05 was 
considered statistically significant.
Results
MIN6 β-cell line transfection efficiency screening
The MIN6 β-cell line is relatively difficult to transfect compared to some continuous cell lines such as HeLa and HEK-293T so eight commercially available transfection reagents were screened for their utility in delivering a GFP plasmid to MIN6 b-cells to drive GFP expression. 
Sorting of GFP fluorescent cells 48 hours post-transfection indicated that the jetPRIME® reagent in a 1:2 DNA to transfection reagent ratio (w/v) was the most effective of the eight 
compounds tested, with almost 30% of cells positive for GFP expression. All other reagents 
tested failed to reach these transfection efficiency levels, with only two other reagents (FuGENE® 6 and TorpedoDNA) having transfection efficiencies in excess of 10%. jetPRIME® was therefore used for all subsequent transfection protocols described herein.
CRISPR-Cas9-mediated knock-down of MIN6 β-cell GPRC5BCRISPR-Cas9 technology was used to induce Gpcr5b-targeted double strand breaks at the genomic locus in MIN6 b-cells. Individual puromycin-resistant transfected cells were expanded and screened for Gpcr5b-targeted double strand breaks using PCR and Sanger 
sequencing. A single stable Gpcr5b KD MIN6 β-cell line, in which the sequence homology 
was reduced to the first 29 amino acids of the 410 amino acids of full length Gprc5b, with the additional introduction of an early stop codon downstream (Fig. 1A), was used as a starting point for further experiments where Gprc5b was transiently re-introduced into the cells. 
Western blotting confirmed Gprc5b knockdown in these cells, with approximately 60% 
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Fig. 3. Effect of Gprc5b expression on MIN6 
β-cell proliferation. Gpcr5b KD MIN6 β-cells (0%) were transfected with increasing concentrations 
of mouse Gprc5b plasmid (0.01-100%) using jetPRIME®. Proliferation was determined by 
quantification of BrdU incorporation into newly synthesised DNA. Data are presented as absorbance 
values (450 nm). Values are expressed as means + 
SEM; n=6-8. **p<0.01.
reduction in Gprc5b protein expression in the KD cells compared to protein-matched WT MIN6 cells (Fig. 1B, C).
Graded re-introduction of Gprc5b into MIN6 β-cells
Gprc5b was re-introduced into the Gprc5b KD MIN6 β-cell line by transient transfec-tion with increasing concentrations of mouse Gprc5b plasmid. It can be seen from Fig. 2 that 
CRISPR-Cas9-targeted deletion of Gprc5b resulted in significant reduction in Gprc5b mRNA levels compared to WT MIN6 b-cells, as expected. Delivery of 0.01-100% of the Gprc5b plas-mid to Gprc5b KD cells resulted in a concentration-dependent increase in Gprc5b mRNA 
expression, such that cells transfected with 100% mouse Gprc5b plasmid had a 1,340-fold up-regulation of Gprc5b (Fig. 2).
Fig. 1. Generating a Gpcr5b KD MIN6 
β-cell line using CRISPR-Cas9 tech-nology. A) Sche-matic representa-tion of the DNA sequence targeted using CRISPR-Cas9 technology to gen-erate a Gpcr5b KD MIN6 monoclonal cell clone, highlight-ing the deleted nu-cleotides in the KD sequence, leading to frame shift muta-tions and followed by several novel stop codons, truncating the protein expression. B) Western blotting vali-
dation of Gprc5b KD in a MIN6 β-cell clone, compared to protein-matched WT MIN6 cells. C) Densitometric 
analysis of GPRC5B protein expression in KD and WT MIN6 cells, normalised to beta-actin. Values are means 
+ range; n=2. **p<0.01.
TGCCTCCGTGGCTTCAGAGAACGCCAGCACGTCCCGGGGCTGTGGACTGG – Gprc5b WT DNA sequence 
TGCCTCCGTGGCTTCAGAGAXCGTXXGXXXXXCCCGGGGCTGTGGACTGG – Gprc5b KD DNA sequence 
Mouse Gprc5b gene location: Chromosome 7: 118,972,047-118,995,211 
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Fig. 2. Gprc5b mRNA expression in MIN6 β-cell lines. 
Gpcr5b KD MIN6 β-cells (0%) were transfected with increasing concentrations of mouse Gprc5b plasmid 
(0.01-100%) using jetPRIME®. Data are normalised relative to the reference gene Gapdh and presented 
as expression relative to WT MIN6 β-cells. Values 
are expressed as means + SEM; n=3. ***p<0.001; 
**p<0.01.
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Effect of Gprc5b expression on MIN6 β-cell proliferationThe role of Gprc5b in b-cell proliferation was investigated using Gpcr5b KD MIN6 
β-cells transfected with increasing concentrations of mouse Gprc5b plasmid. There was no 
significant difference between the rate of proliferation of WT MIN6 β-cells and Gpcr5b KD 
MIN6 β-cells, but re-introduction of Gprc5b induced a concentration-dependent stimulation of BrdU incorporation into proliferating MIN6 cells, with maximal effects achieved in cells 
that had been transfected with 100% of the plasmid (Fig. 3).
Effect of Gprc5b expression on MIN6 β-cell apoptosisIt can be seen from Fig. 4A that deletion of Gprc5b did not affect basal apoptosis of 
MIN6 β-cells, but cells that had been transfected with 100% of the mouse Gprc5b plasmid 
showed a significant elevation in caspase 3/7 activities. Similar pro-apoptotic effects of over-expression of Gprc5b were observed under conditions where enhanced apoptosis was induced by a mixed cytokine cocktail (Fig. 4B) or by the saturated long chain fatty acid 
palmitate (Fig. 4C). Thus, exposure of Gpcr5b KD MIN6 β-cells for 20 hours to a cocktail 
of TNFα, IFNg and IL-1β or to 500µM palmitate promoted 3-fold and 2-fold elevations in apoptosis, respectively, and this was further increased in a concentration-dependent manner by re-introduction of Gprc5b.
Signalling pathway screening by re-introduction of Gprc5b into MIN6 β-cellsGprc5b is expressed by islets where it may play an important role in b-cell function [11], but the molecular signalling pathways downstream of Gprc5b in b-cells have not been previ-
ously identified. Transfection of Gpcr5b KD MIN6 β-cells with 10% mouse Gprc5b plasmid 
(bulked to 100% using empty pcDNA3) resulted in identification of several cascades that 
were specifically and consistently up-regulated (Fig. 5). Consistent with the MIN6 b-cell ap-optosis data provided here, 3 of the top 4 array pathways (progesterone receptor, TGF-b and IFNg) are reported to be pro-apoptotic in b-cells [19-21]. In addition, Gprc5b over-expression 
Fig. 4. Effect of Gprc5b expression on MIN6 β-cell apoptosis. Gpcr5b KD MIN6 β-cells (0%) were transfected 
with increasing concentrations of mouse Gprc5b plasmid (0.01-100%) using jetPRIME®. Basal (A), 
cytokine- (B) and palmitate- (C) induced apoptosis was quantified by measuring caspase 3/7 activities. Data 
are expressed as relative light units (RLU). Values are means + SEM; n=6. *p < 0.05; **p<0.01; ***p<0.001.
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was associated with up-regu-lation of the pro-proliferative E2F transcription factor [22] and down-regulation of HN4a, a repressor of proliferation [23], in keeping with our observa-tions of enhanced proliferation following increased Gprc5b ex-pression in MIN6 b-cells.
Gprc5b regulates TGF-β and 
IFNγ signalling pathways in 
MIN6 β-cells.Two key Gprc5b-regulat-
ed pathways identified by the Cignal Reporter Arrays, TGF-b and IFNg, were further probed by western blotting of MIN6 
β-cells using antibodies direct-ed against SMAD2/3 and STAT1, proteins downstream of TGF-b and IFNg signalling. Transfec-
tion of Gprc5b KD MIN6 β-cells 
with 10% mouse Gprc5b plas-mid had no effect on total SMAD2/3 (Fig. 6A) or STAT1 (Fig. 6B) expression, but phos-phorylated, active SMAD2/3 (Fig. 6A, C) and STAT1 (Fig. 6B, 
D) proteins were significantly 
higher following β-cell over-expression of Gprc5b. We also 
quantified expression of mRNAs encoding Nodal and DP5, which signal through SMAD2/3 [20] and STAT1[21] cascades re-spectively. Nodal and DP5 mR-
NAs were significantly reduced following CRISPR-mediated 
knock-down of Gprc5b expression, and cells that had been transfected with 10% Gprc5b plasmid showed substantial up-regulation of Nodal mRNA (Fig. 6E), while DP5 mRNA was 
not significantly elevated (Fig. 6F).
DiscussionInsulin-secreting cell lines represent an alternative platform to primary islet b-cells for studying biological and physiological processes, and they may be genetically manipulated 
by transfection to investigate the roles of specific genes. MIN6 β-cells retain many of the physiological characteristics of primary mouse b-cells, and they have been extensively used for functional studies [24, 25]. However, MIN6 b-cells are not particularly amenable to 
transfection, which has led to difficulties in modifying gene expression for functional analyses [26, 27]. In this study we identified that jetPRIME® was the most effective candidate for use 
with MIN6 β-cells, with a transfection efficiency of ~30% at 48 hours.
Fig. 5. Gprc5b-regulated signalling in MIN6 β-cells. Gprc5b KD 
MIN6 β-cells were transfected with 10% mouse Gprc5b plasmid  or 
100% pcDNA3 vector and with Cignal Array reporter constructs. Pathway reporters are listed by decreasing values of log2 ratio 
fold-changes in cells transfected with 10% mouse Gprc5b plasmid compared to cells transfected with pcDNA3. Data are expressed as means + range; n =2.
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GPCRs represent the largest superfamily and most diverse group of mammalian 
transmembrane proteins and over 30% of currently marketed drugs target human GPCRs [8, 28]. Orphan receptors, those whose endogenous ligand has not yet been identified, have huge potential in biomedical research and drug development, including in the regulation of islet function [29]. One of these orphan receptors, GPRC5B, is widely expressed in human and mouse islets [11, 30], and we have previously reported that Gprc5b down-regulation increases 
insulin secretion and promotes β-cell survival [11]. In addition, GPRC5B expression was up-regulated in human islets from type 2 diabetic donors, suggesting a possible association 
between this receptor and β-cell dysfunction in diabetes [11]. Moreover, Gprc5b has also been associated with diet-induced obesity and T2D [13], with confirmed high expression by white adipose tissue [31].
Since no endogenous ligands have been identified for GPRC5B, we have adopted the approach of stably down-regulating this receptor in b-cells and then increasing its expression 
through transient transfection. We developed a standardised protocol for producing modified 
isogenic stable MIN6 β-cell clones under-expressing Gprc5b using CRISPR-Cas9 technology, 
in which a non-specific CRISPR-associated endonuclease, directed by a guide RNA molecule 
Fig. 6. Gpcr5b regulation of TGF-β and IFNg signalling pathways in MIN6 b-cells. Gprc5b KD MIN6 β-cells 
were transfected with 100% empty pcDNA3 vector (KD) or with 10% mouse Gprc5b plasmid (10% Gprc5b) and harvested 48 hours post-transfection. (A, B) Fractionated proteins were immunoanalyzed for total and phosphorylated SMAD2/3 and STAT1 proteins, and compared to beta-actin expression in the same samples. 
(C, D) Densitometric analysis of phosphorylated SMAD2/3 (C) and STAT1 (D) normalised to beta-actin. Val-
ues are means + SEM; n=4. ***p<0.001. (E, F) Quantification of mRNAs encoding Nodal (E) and DP5 (F) in 
WT MIN6 β-cells and in Gprc5b KD MIN6 β-cells transfected with or without 10% Gprc5b plasmid. Data are 
normalized to Gapdh. Values are means + SEM; n = 5. *p < 0.05; ***p<0.001 relative to expression in KD cells.
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to a specific DNA sequence, snips DNA like a pair of molecular scissors [32, 33]. This approach causes permanent and irreversible insertions, deletions or frameshifts in the targeted sequence, in contrast to RNA interference methods that result in a temporary reduction in protein expression. The increased proliferation and apoptosis observed following over-
expression of Gprc5b in MIN6 β-cells suggests that this receptor can signal constitutively, as has been observed for other GPCRs [34], or that the β-cells express an endogenous agonist for Gprc5b, which can have autocrine effects when the receptor is expressed at high levels.High-performance cell-based assays allow screening of multiple signalling activities simultaneously to identify relevant pathways for further analysis [35]. Using the Cignal™ 
45-Pathway Reporter Array platform and the Gprc5b KD MIN6 β-cell line, we identified that apoptosis and proliferation pathways were up-regulated after Gprc5b plasmid transfection, and the anti-proliferative HNF4a pathway was down-regulated. We then focused on 
the IFNγ-regulated transcription factor STAT1 and TGF-β-regulated transcription factor 
SMAD2/3 as these proteins have previously been reported to promote β-cell apoptosis [20, 21]. Up-regulation of the TGF-β and IFNg pro-apoptotic signalling pathways following re-introduction of Gprc5b into Gprc5b KD MIN6 b-cells was confirmed by western blotting. We 
also identified that Gprc5b KD MIN6 β-cells had lower levels of mRNAs encoding the pro-apoptotic proteins Nodal and DP5, which have been implicated in induction of b-cell death [20, 21, 36]. The down-regulation of these mRNAs in the Gprc5b KD MIN6 β-cells was not associated with reduced basal levels of apoptosis, most likely because unstimulated apoptosis in MIN6 b-cells is very low and not readily amenable to further reduction. The increase in Nodal mRNA following over-expression of Gprc5b is consistent with Gprc5b promoting 
b-cell apoptosis through a Nodal/Smad2/3 pathway, as has been reported for INS-1 insulin-secreting cells [20]. The role of DPF5 is less clear, because although its regulation by Gprc5b 
is implicated by the reduction in its expression in Gprc5b KD MIN6 β-cells, receptor over-
expression did not significantly up-regulate DP5 mRNA levels. Nonetheless, the array and western blotting data indicate that Gprc5b activates IFNg/STAT1 signalling in b-cells and the reduction in DP5 following Gprc5b knock-down suggests a role for this pro-apoptotic protein downstream of Gprc5b.
In addition to increased signalling through pro-apoptotic pathways, we also identified that Gprc5b couples to signalling via E2F, which is known to promote b-cell proliferation [37, 38], and its down-regulation of HNF4a signalling is consistent with the reported role of this transcription factor as an inhibitor of proliferation [23] and the effects of an HNF4a antagonist to stimulate b-cell proliferation [39]. It is unusual for individual receptors to be 
coupled to pathways that induce both apoptosis and proliferation, as has been identified here for Gprc5b, but it is possible that enhanced proliferation is required to compensate for the potentially deleterious effects of activation of the pro-apoptotic cascades described above.
Conclusion
In summary, we have used the CRISPR-Cas9 technology to specifically reduce Gprc5b 
expression in MIN6 β-cells, and used this model for graded re-introduction of this receptor 
for functional analyses. We have confirmed that Gprc5b promotes b-cell apoptosis, most likely through activation of the TGFb/Nodal/SMAD2/3 and IFNg/STAT1/DP5 signalling pathways, making it an appealing target for development of inhibitors to treat T2D.
Acknowledgements
The study was designed by SA, PA and SJP. Data were collected and analysed by PA, IRM, 
RH and BL. The article was drafted by PA, SA and SJP. All authors revised the article critically 
for intellectual content and gave their approval of this version to be published. PA, SJP and 
Cell Physiol Biochem 2018;45:656-666
DOI: 10.1159/000487159
Published online: February 05, 2018 665
Cellular Physiology 
and Biochemistry
© 2018 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cpb
Atanes et al.: CRISPR-Cas9 Technology to Identify Gprc5b Signalling in MIN6 β-Cells
SA take responsibility for the contents of the article. This study was supported by grants from the EFSD/Boehringer-Ingelheim Research Programme and a Diabetes UK RD Lawrence Fellowship to SA (11/0004172). All authors declare that they have no competing interests.
Disclosure StatementThe authors have nothing to disclose.
References
1 Kim EJ, Kang KH, Ju JH: CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells. 
Korean J Intern Med 2017;32:42-61.
2 Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K: Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013;12:393-394.
3 Abrahimi P, Chang WG, Kluger MS, Qyang Y, Tellides G, Saltzman WM, Pober JS: Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res 2015;117:121-128.
4 Naylor J, Suckow AT, Seth A, Baker DJ, Sermadiras I, Ravn P, Howes R, Li J, Snaith MR, Coghlan MP, Hornigold 
DC: Use of CRISPR/Cas9-engineered INS-1 pancreatic beta cells to define the pharmacology of dual GIPR/
GLP-1R agonists. Biochem J 2016;473:2881-2891.
5 Bompada P, Atac D, Luan C, Andersson R, Omella JD, Laakso EO, Wright J, Groop L, De Marinis Y: Histone 
acetylation of glucose-induced thioredoxin-interacting protein gene expression in pancreatic islets. Int J Biochem Cell Biol 2016;81:82-91.
6 Wang Q, Pronin AN, Levay K, Almaca J, Fornoni A, Caicedo A, Slepak VZ: Regulator of G protein signaling 
Gbeta5-R7 is a crucial activator of muscarinic M3 receptor-stimulated insulin secretion. FASEB J 
2017;10.1096/fj.201700197RR7 Basiri M, Behmanesh M, Tahamtani Y, Khalooghi K, Moradmand A, Baharvand H: The Convenience of Single 
Homology Arm Donor DNA and CRISPR/Cas9-Nickase for Targeted Insertion of Long DNA Fragment. Cell J 2017;18:532-539.
8 Stockert JA, Devi LA: Advancements in therapeutically targeting orphan GPCRs. Front Pharmacol 2015;6:100.9 Persaud S: Islet G-protein coupled receptors: therapeutic potential for diabetes. Current Opinion in Pharmacology 2017;37:24-28.
10 Chung HJ, Kim JD, Kim KH, Jeong NY: G protein-coupled receptor, family C, group 5 (GPRC5B) 
downregulation in spinal cord neurons is involved in neuropathic pain. Korean J Anesthesiol 2014;66:230-236.11 Soni A, Amisten S, Rorsman P, Salehi A: GPRC5B a putative glutamate-receptor candidate is negative modulator of insulin secretion. Biochem Biophys Res Commun 2013;441:643-648.
12 Robbins MJ, Charles KJ, Harrison DC, Pangalos MN: Localisation of the GPRC5B receptor in the rat brain and spinal cord. Brain Res Mol Brain Res 2002;106:136-144.
13 Kim YJ, Sano T, Nabetani T, Asano Y, Hirabayashi Y: GPRC5B activates obesity-associated inflammatory signaling in adipocytes. Sci Signal 2012;5:ra85.
14 Amisten S, Braun OO, Bengtsson A, Erlinge D: Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008;122:47-57.
15 Amisten S: Quantification of the mRNA expression of G protein-coupled receptors in human adipose tissue. Methods Cell Biol 2016;132:73-105.
16 Amisten S: A rapid and efficient platelet purification protocol for platelet gene expression studies. Methods Mol Biol 2012;788:155-172.
17 Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
18 Liu B, Barbosa-Sampaio H, Jones PM, Persaud SJ, Muller DS: The CaMK4/CREB/IRS-2 cascade stimulates proliferation and inhibits apoptosis of beta-cells. PLoS One 2012;7:e45711.
Cell Physiol Biochem 2018;45:656-666
DOI: 10.1159/000487159
Published online: February 05, 2018 666
Cellular Physiology 
and Biochemistry
© 2018 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cpb
Atanes et al.: CRISPR-Cas9 Technology to Identify Gprc5b Signalling in MIN6 β-Cells
19 Zhou R, Yao X, Xu X, Wang G, Zhu Z, Chen J, Chen L, Shen X: Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability. Steroids 2013;78:987-995.
20 Zhao F, Huang F, Tang M, Li X, Zhang N, Amfilochiadis A, Li Y, Hu R, Jin T, Peng C, Wang Q: Nodal induces 
apoptosis through activation of the ALK7 signaling pathway in pancreatic INS-1 beta-cells. Am J Physiol Endocrinol Metab 2012;303:E132-143.21 Moore F, Naamane N, Colli ML, Bouckenooghe T, Ortis F, Gurzov EN, Igoillo-Esteve M, Mathieu C, Bontempi G, Thykjaer T, Orntoft TF, Eizirik DL: STAT1 is a master regulator of pancreatic {beta}-cell apoptosis and 
islet inflammation. J Biol Chem 2011;286:929-941.
22 Duronio RJ, Xiong Y: Signaling pathways that control cell proliferation. Cold Spring Harb Perspect Biol 2013;5:a008904.23 Walesky C, Apte U: Role of hepatocyte nuclear factor 4alpha (HNF4alpha) in cell proliferation and cancer. Gene Expr 2015;16:101-108.
24 Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki JI, Oka Y: Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 1993;36:1139-1145.
25 Persaud SJ, Hauge-Evans AC, Jones PM: Chapter 15 - Insulin-Secreting Cell Lines: Potential for Research and Diabetes Therapy A2 - Ulloa-Aguirre, Alfredo; in  (Conn PM, ed)  Cellular Endocrinology in Health and Disease. Boston,  Academic Press, 2014, vol. https://doi.org/10.1016/B978-0-12-408134-5.00015-9p.^pp. 239-256.
26 Harbeck MC, Chepurny O, Nikolaev VO, Lohse MJ, Holz GG, Roe MW: Simultaneous optical measurements of cytosolic Ca2+ and cAMP in single cells. Sci STKE 2006;2006:pl6.
27 Lai E, Bikopoulos G, Wheeler MB, Rozakis-Adcock M, Volchuk A: Differential activation of ER stress 
and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2008;294:E540-550.28 Rask-Andersen M, Almen MS, Schioth HB: Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011;10:579-590.
29 Ngo T, Kufareva I, Coleman J, Graham RM, Abagyan R, Smith NJ: Identifying ligands at orphan GPCRs: 
current status using structure-based approaches. Br J Pharmacol 2016;173:2934-2951.
30 Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ: An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol Ther 2013;139:359-391.
31 Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, Gloger I, Sims M, Middlemiss DN, Pangalos MN: Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics 2000;67:8-18.
32 Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E: Intervening sequences of regularly spaced 
prokaryotic repeats derive from foreign genetic elements. J Mol Evol 2005;60:174-182.
33 Pourcel C, Salvignol G, Vergnaud G: CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 2005;151:653-663.34 Chalmers DT, Behan DP: The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov 2002;1:599-608.35 Eglen RM, Gilchrist A, Reisine T: The use of immortalized cell lines in GPCR screening: The good, bad and ugly. Combinatorial Chemistry & High Throughput Screening 2008;11:560-565.36 Gurzov EN, Ortis F, Cunha DA, Gosset G, Li M, Cardozo AK, Eizirik DL: Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis. Cell Death Differ 2009;16:1539-1550.
37 Tessem JS, Moss LG, Chao LC, Arlotto M, Lu D, Jensen MV, Stephens SB, Tontonoz P, Hohmeier HE, Newgard CB: Nkx6.1 regulates islet beta-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors. Proc Natl Acad Sci U S A 2014;111:5242-5247.38 Furuya F, Shimura H, Yamashita S, Endo T, Kobayashi T: Liganded thyroid hormone receptor-alpha 
enhances proliferation of pancreatic beta-cells. J Biol Chem 2010;285:24477-24486.39 Lee SH, Piran R, Keinan E, Pinkerton A, Levine F: Induction of beta-cell replication by a synthetic HNF4alpha antagonist. Stem Cells 2013;31:2396-2407.
